论文部分内容阅读
本文回顾性分析Valsartan Heart Failure Trial(Val-HeFT)数据库,评价有症状充血性心力衰竭(CHF)患者心房颤动(Af)发生率,确定发生Af的预测因素,评价缬沙坦对Af的预防作用。 Val-HeFT是一项随机双盲对照平行试验。入选标准:年龄≥18岁,既往有HF病史及临床表现至少持续3个月,Ⅱ-Ⅳ级心功能(NYHA),病情稳定,服用血管紧张素转换酶抑制剂 (ACEI)、利尿剂、地高辛、β阻滞剂至少2周,左室射血分数 (LVEF)<40％,超声心动图测定的左室舒张期内径／体表面积
This article retrospectively analyzed the Valsartan Heart Failure Trial (Val-HeFT) database to evaluate the incidence of atrial fibrillation (Af) in patients with symptomatic congestive heart failure (CHF), determined the predictors of Af onset, and evaluated the preventive effects of valsartan on Af . Val-HeFT is a randomized double-blind controlled parallel experiment. Inclusion criteria: age> 18 years old, previous history of HF and clinical manifestations for at least 3 months, grade Ⅱ-Ⅳ cardiac function (NYHA), stable condition, taking angiotensin-converting enzyme inhibitor (ACEI), diuretics, Digoxin, beta blockers for at least 2 weeks, left ventricular ejection fraction (LVEF) <40%, left ventricular diastolic diameter / body surface area measured by echocardiography